Thrill Seekers Might Like 2 Downtrodden Stocks Insiders Are Buying
TherapeuticsMD and Spark Networks are beaten-down names with recent buying interest from insiders in common.
Market Participants Are Battling Omicron Pessimism
There are a number of issues to consider from a trading standpoint as we start the week.
Fingers Crossed for a Small-Cap Revenge Rally in 2022
The lingering effects of the pandemic have been hard on smaller biotech and healthcare stocks, but the worm could turn next year.
How to Play AstraZeneca as Earnings Approach
Let's see how the charts are shaping up ahead of the numbers Friday.
GE Plans to Split Into 3: Here's MY Plan
Since GE CEO Larry Culp took the reins three years ago his plan has been nothing if not aggressive.
Options Play of the Week: Dipping Into Dynavax
Knee-jerk reactions to earnings results can create attractive opportunities.
Buying Moderna Now Could Be Akin to Trying to Catch a Falling Knife
Here's what traders can do.
Will Humana's Earnings Numbers Generate an Upside Breakout?
Let's take a look at the charts of this healthcare provider ahead of Wednesday's report.
Centene Is Rallying, but Don't Chase Its Shares
There is resistance overhead for the stock of the health plan operator after a spurt upward, so wait to buy it on a breakout over a key price.
I See Some Magic Happening as Psilocybin Advances
New technology could take out some of the pain -- and subjectivity -- for those looking to invest in this emerging line of treatments.